港股异动丨康希诺涨超7%，2025年扭亏为盈

Core Viewpoint - The company, CanSino Biologics (6185.HK), reported a significant turnaround in its financial performance, achieving a profit of 27.87 million yuan for the year ending last December, compared to a loss of 379 million yuan in the previous year [1] Financial Performance - The total revenue for the company reached 1.068 billion yuan, marking a year-on-year increase of 26.18% [1] - The company successfully transitioned from a loss to a profit, indicating effective management and operational improvements [1] Strategic Focus - The company continues to implement a development strategy centered on innovation and commercialization [1] - There has been a strong emphasis on cost reduction and efficiency enhancement, with effective control over various expenses [1] - The optimization of production and sales coordination has contributed to an increase in gross margin [1]